

- (b) a second source of protein which comprises a source of intact protein in a quantity sufficient to yield a stable emulsification of the soy protein hydrolysate and the intact protein in the nutritional product;
- (c) an emulsifier selected from the group consisting of diacetyl tartaric acid esters of mono-diglycerides and sodium stearoyl lactylate; and
- (d) a source of fat characterized by the ratio, by weight, of the sum of the n-6 fatty acids to the sum of the n-3 fatty acids being in the range of about 1.3:1 to 2.5:1; the nutritional product having a pH in the range of 6.4 to 6.6 and being a stable emulsion after being subjected to terminal sterilization.
2. A nutritional product for enteral nutritional support of a person infected with human immunodeficiency virus as described in claim 1 where the source of fat comprises fish oil.
3. A nutritional product for enteral nutritional support of a person infected with human immunodeficiency virus as described in claim 2 wherein the intact protein comprises sodium caseinate.
4. A nutritional product for enteral nutritional support of a person infected with human immunodeficiency virus as described in claim 1 further comprising a source of dietary fiber.
5. A nutritional product for enteral nutritional support of a person infected with human immunodeficiency virus as described in claim 4 wherein the intact protein comprises sodium caseinate.
6. A nutritional product for enteral nutritional support of a person infected with human immunodeficiency virus as described in claim 4 wherein the source of dietary fiber comprises soy polysaccharides.
7. A nutritional product for enteral nutritional support of a person infected with human immunodeficiency virus as described in claim 6 wherein the intact protein comprises sodium caseinate.
8. A nutritional product for enteral nutritional support of a person infected with human immunodeficiency virus as described in claim 1 wherein the soy protein hydrolysate has a degree of hydrolysis in the range of about 14 to 17 and the amino acid profile of the soy protein hydrolysate has less than 1% free amino acids.
9. A nutritional product for enteral nutritional support of a person infected with human immunodeficiency virus as described in claim 8 wherein the intact protein comprises sodium caseinate.
10. A nutritional product for enteral nutritional support of a person infected with human immunodeficiency virus as described in claim 1 wherein the intact protein is selected from the group consisting of: sodium caseinates, pea protein isolates and whey protein isolates.
11. A nutritional product for enteral nutritional support of a person infected with human immunodeficiency virus as described in claim 1 wherein the nutritional product has a caloric density of about 1.2 to 1.35 calories per ml.
12. A liquid nutritional product for enteral nutritional support of a person infected with human immunodeficiency virus comprising:
- (a) a first source of protein comprising a soy protein hydrolysate having a degree of hydrolysis in the range of about 14 to 17 and a molecular weight partition, as determined by size exclusion chromatography, wherein 30-60% of the particles have a molecular weight in the range of 1,500-5,000 Daltons and the amino acid profile of the soy protein hydrolysate has less than 1% free amino acids;
- (b) a second source of protein which comprises sodium caseinate, the sodium caseinate comprising by

- weight about 10-30% of the protein in the nutritional product;
- (c) a source of diacetyl tartaric acid esters of mono-diglycerides; and
- (d) a source of fat characterized by the ratio, by weight, of the sum of the n-6 fatty acids to the sum of the n-3 fatty acids being in the range of about 1.3:1 to 2.5:1; the nutritional product having a pH in the range of 6.4 to 6.6 and being a stable emulsion after being subjected to terminal sterilization.
13. A nutritional product for enteral nutritional support of a person infected with human immunodeficiency virus as described in claim 12 further comprising a source of dietary fiber.
14. A nutritional product for enteral nutritional support of a person infected with human immunodeficiency virus as described in claim 12 further comprising soy polysaccharide as a source of dietary fiber.
15. A nutritional product for enteral nutritional support of a person infected with human immunodeficiency virus as described in claim 12 wherein the source of fat comprises fish oil.
16. A nutritional product for enteral nutritional support of a person infected with human immunodeficiency virus as described in claim 12 wherein the source of fat comprises fish oil, canola oil and medium chain triglycerides.
17. A nutritional product for enteral nutritional support of a person infected with human immunodeficiency virus as described in claim 12 wherein the nutritional product has a caloric density of about 1.2 to 1.35 calories per ml.
18. A liquid nutritional product for enteral nutritional support of a person infected with human immunodeficiency virus comprising:
- (a) a first source of protein comprising a soy protein hydrolysate having a degree of hydrolysis in the range of about 14 to 17 and a molecular weight partition, as determined by size exclusion chromatography, wherein 30-60% of the particles have a molecular weight in the range of 1,500-5,000 Daltons and the amino acid profile of the soy protein hydrolysate has less than 1% free amino acids;
- (b) a second source of protein which comprises sodium caseinate, the sodium caseinate comprising by weight about 10-30% of the protein in the nutritional product;
- (c) a source of diacetyl tartaric acid esters of mono-diglycerides; and
- (d) a source of fat comprising canola oil and fish oil characterized by the ratio, by weight, of the sum of the n-6 fatty acids to the sum of the n-3 fatty acids being in the range of about 1.3:1 to 2.5:1, and
- (e) dietary fiber in the form of soy polysaccharide; the nutritional product having a caloric density in the range of about 1.2 to 1.35 calories per ml; the nutritional product having a pH in the range of 6.4 to 6.6 and being a stable emulsion after being subject to terminal sterilization.
19. A nutritional product for enteral nutritional support of a person infected with human immunodeficiency virus as described in claim 18, further comprising β -carotene.
20. A nutritional product for enteral nutritional support of a person infected with human immunodeficiency virus as described in claim 18, further comprising per liter: (a) about 970 to 1020 mg of sodium; (b) about 2600 to 2750 mg of potassium; and (c) about 1400 to 1500 mg of chloride.